Related Experiment Video
Updated: Jul 28, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF
1INSERM U.143 Hôpital de Bicêtre, Paris, France.
Abstract:
A protease present in plasma cleaves von Willebrand factor (vWF) at the peptide bond 842Tyr-843Met of the mature subunit. To quantify this vWF-cleaving protease activity in plasma we have developed a simple method based on the estimation by IRMA of the degradation of a constant amount of wild type recombinant vWF used as substrate, by serial dilutions of test plasma used as protease provider. vWFAg was estimated by two-site IRMA using as first coating antibody a monoclonal antibody (MoAb) whose epitope is localized on the C-terminal side of the cleavage site, and as second labeled antibody a pool of MoAbs specific for the N-terminal side. Because the proteolytic process leads to the progressive separation of the C- and N-terminal portions of the vWF subunit such an IRMA also shows a progressive apparent loss of vWFAg. In contrast, the levels of vWFAg estimated after proteolysis by regular IRMA remained essentially constant. Results obtained with this new method were compared with the analysis by SDS-agarose gel electrophoresis of the multimeric pattern of proteolyzed WT-rvWF and no significant difference was noted testing a series of 28 plasmas. As compared with normal pooled plasma, 14 normal individuals and 13 patients with various types of vWD had normal levels of protease activity (44-178%) by both methods. The validity of the method was confirmed by showing a lack of detectable protease activity in a patient with chronic relapsing thrombotic thrombocytopenic purpura. In conclusion our method appears as a useful tool for the quantification of the vWF-cleaving protease activity in plasma. Its sensitivity and specificity are similar to those of SDS-gel electrophoresis. However, this new IRMA has the major advantages of being much simpler and faster, and open to most research laboratories in the field.
Insights
A new immunoassay method quantifies von Willebrand factor (vWF)-cleaving protease activity in plasma. This simple, rapid assay is comparable to gel electrophoresis for diagnosing vWF disorders.
Area of Science:
- Biochemistry
- Hematology
- Immunology
Background:
- Plasma contains a protease that cleaves von Willebrand factor (vWF) at a specific site.
- Quantifying this vWF-cleaving protease activity is crucial for understanding vWF-related disorders.
Purpose of the Study:
- To develop and validate a simple, rapid immunoassay method for quantifying vWF-cleaving protease activity in plasma.
- To compare the new method with existing techniques like SDS-agarose gel electrophoresis.
Main Methods:
- Developed a two-site IRMA using specific monoclonal antibodies to detect vWF degradation.
- Used serial dilutions of test plasma as the protease source and wild-type recombinant vWF as the substrate.
- Compared IRMA results with SDS-agarose gel electrophoresis analysis of vWF multimer patterns.
Main Results:
- The IRMA method accurately reflected vWF degradation, showing a progressive apparent loss of vWF antigen (vWFAg).
- Results correlated well with SDS-agarose gel electrophoresis findings across 28 plasma samples.
- The method demonstrated normal protease activity in healthy individuals and patients with vWD, and lacked detectable activity in a patient with thrombotic thrombocytopenic purpura.
Conclusions:
- The developed IRMA is a simple, fast, and reliable tool for quantifying plasma vWF-cleaving protease activity.
- This assay offers comparable sensitivity and specificity to gel electrophoresis but is more accessible to research laboratories.
- The method is valuable for diagnosing and studying vWF-related disorders.
More Related Videos
08:30Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
08:50Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026